Skip to main content

Perioperative Antibiotic Prophylaxis

Category: Pharmacology > Infection & Prophylaxis Last updated: September 2026

Overview​

Perioperative antibiotic prophylaxis aims to reduce surgical site infection (SSI) by achieving adequate tissue and urinary antibiotic concentrations at the time of incision. The foundational guidance for urologic prophylaxis is the AUA Best Practice Statement (BPS) 2020 on urologic procedures and antimicrobial prophylaxis[1] and the ASHP/IDSA 2013 antimicrobial prophylaxis in surgery guideline.[2]

A second and increasingly important framework is the device-specific evidence for IPP, AUS, mesh, and sacrocolpopexy — particularly the PUMP collaborative 2023–2025 data showing that AUA-recommended vancomycin-plus-gentamicin is associated with higher IPP infection rates than nonstandard alternatives, reshaping the prosthetic-urology antibiotic conversation. See Penile implants — infection and Prosthetic infection & biofilm protocols for the full device-specific detail.

Mechanism of Action​

Perioperative prophylaxis provides time-limited antimicrobial coverage during the window of maximum contamination risk — from skin incision to closure. The mechanistic requirements are:

  1. Adequate tissue concentration at time of incision → timing critical
  2. Broad enough coverage for expected contaminants → agent selection by procedure type
  3. Sufficient duration to cover the operative window → redose intravascular half-life
  4. Short enough total exposure to preserve microbiome and avoid resistance → single-dose or <24-hour courses

Agents Used​

AgentPrimary roleTypical dose (normal renal function)Redose interval
CefazolinWorkhorse for most urologic procedures; skin + common gram-negatives2 g IV (3 g if ≥120 kg)q4h
VancomycinSelected MRSA coverage; procedure-specific alternative when cefazolin is unsuitable15 mg/kg IVUsually no intraoperative redose
GentamicinGram-negative coverage; prosthetic device cases (AUA BPS 2020)5 mg/kg IV (single dose)Single dose typically
Piperacillin-tazobactamBroad gram-negative + anaerobic coverage; urinary diversion / bowel-involving cases3.375 g IVq2h
CeftriaxoneAlternative to cefazolin; longer half-life2 g IVLong t½ — single dose usually sufficient
MetronidazoleAnaerobic coverage — combine with cephalosporin for bowel cases500 mg IVUsually no intraoperative redose
Clindamycinβ-lactam allergy; skin coverage900 mg IVq6h
AztreonamGram-negative alternative; check ceftazidime allergy because of shared side chain2 g IVq4h

Adult reference doses and redosing intervals above follow ASHP guidance for normal renal function; intervals run from the start of the preceding dose. Gentamicin uses actual weight unless obesity requires a dosing weight (IBW + 0.4 × excess above IBW). Antifungal selection is discussed in the device and antifungal hubs; it is not routine prophylaxis for every implant.[2][21]

Indications in Urology — AUA BPS 2020 Framework​

The AUA BPS categorizes urologic procedures by infection risk. Single-dose perioperative prophylaxis is the standard for most clean-contaminated procedures.[1]

Choose by procedure, culture and local susceptibility​

ProcedureProphylaxis framework
TURP / HoLEPSingle-dose prophylaxis; select gram-negative and, where relevant, enterococcal coverage from culture/local guidance
TURBTAUA supports single-dose prophylaxis; EAU specifically recommends it for patients at high risk of postoperative sepsis
Ureteroscopy / PCNLProcedure-specific prophylaxis; identify and treat relevant preoperative infection / bacteriuria
UrethroplastyPerioperative prophylaxis; buccal harvest or a perineal incision alone does not justify prolonged postoperative antibiotics
Sling / mesh / sacrocolpopexyFollow the relevant vaginal / abdominal procedure protocol; merely entering the peritoneum does not itself require added anaerobic coverage
IPP / AUSStandard perioperative prophylaxis remains indicated; see device-specific discussion
Cystectomy / bowel-containing diversionMatch coverage to bowel segment, obstruction/contamination and local protocol; a nonobstructed small-bowel segment and colorectal entry are not identical exposures

The AUA and EAU recommendations are not identical for every procedure. Avoid turning this overview into a universal cefazolin-or-gentamicin order set.[1][2][20]

Procedures usually not requiring prophylaxis​

Healthy, low-risk adults generally do not require prophylaxis for simple cystoscopy or routine urodynamics. Routine catheter exchange does not become an antibiotic indication merely because asymptomatic bacteriuria is present. SWL without bacteriuria or suspected infection generally does not require prophylaxis. Check patient-specific infection risks and the actual procedure.[1][3][7][20]

Preoperative urine culture and asymptomatic bacteriuria​

The AUA BPS 2020 requires preoperative evaluation with dipstick, microscopy, and/or formal culture scaled to procedural risk, and explicitly warns that urine culture should not be interpreted without accompanying urine microscopy because sample contamination and benign colonization are common. Defer elective procedures when active infection requires treatment. For urgent infection or obstruction, obtain cultures when feasible and start appropriate treatment / source control; do not delay necessary drainage while waiting for susceptibility results.[1]

IDSA asymptomatic-bacteriuria guideline (2019)[7] provides the cleanest framework:

Clinical scenarioIDSA 2019 recommendationStrength / evidence
Endoscopic urologic procedure with mucosal trauma (TURP, TURBT, URS)Screen for and treat ASBStrong / Moderate
Prior to AUS or penile prosthesis implantationDo not routinely screen or treat ASB; still give standard perioperative prophylaxisWeak / Very low
When treating ASB before a GU procedureUse culture-targeted therapy, not empiricWeak
Duration when treating ASB for GU procedure1–2 doses starting 30–60 min preop; not a prolonged courseWeak

The prosthetic-device exception exists because implant infections are typically caused by biofilm-producing skin flora rather than urinary pathogens — a retrospective analysis of 721 AUS and IPP cases found similar device-infection rates with and without preoperative bacteriuria (3% vs 4.3%), and only 1 of 15 device infections matched the preop urine organism.[7]

The prospective TOCUS cohort (2,389 procedures) associated positive preoperative urine cultures and prior UTI with postoperative infection. This observational association does not establish that a longer preventive course eliminates risk; continue culture-directed planning and postoperative clinical surveillance.[15]

Device-Specific Protocols​

IPP: retrospective multicenter PUMP analyses found associations between regimen choice and infection. In the 5,261-patient study, antifungal use had adjusted OR 0.22 (78% lower odds, not a 92% risk reduction). These data do not establish a universal three-drug regimen or a causal antifungal benefit. Prolonged IV prophylaxis and postoperative oral antibiotics have not shown a clear preventive benefit in these observational studies.[4][5][6]

AUS and mesh: do not extrapolate the IPP antifungal association into a routine recommendation. National IPP/AUS cohort analyses found mixed associations between guideline adherence and downstream outcomes; confounding limits causal interpretation, and they do not prove a particular regimen is microbiologically inadequate.[13][14]

Use the prosthetic infection & biofilm hub for the device-specific evidence and manufacturer handling restrictions. InhibiZone and hydrophilic devices have different preparation requirements; do not transfer a dip or irrigation recipe between products. Operative handling belongs on the implant infection page.

Prostate biopsy — current EAU 2026 guidance​

Transperineal biopsy is preferred for its lower infectious risk and antibiotic stewardship. EAU 2026 weakly recommends omitting perioperative antibiotics in transperineal biopsy patients without infection risk factors. This does not apply automatically to active infection or high-risk patients.[20]

The NORAPP trial randomized 555 patients; 553 were analyzed (277 prophylaxis, 276 none). Neither group had sepsis or UTI requiring hospitalization. Outpatient UTI occurred in 1/277 versus 3/276. The prespecified noninferiority margin was 4%; patients with high infection risk or ongoing infection were excluded.[9]

Transrectal biopsy: use rectal povidone-iodine preparation plus locally appropriate prophylaxis. EAU prioritizes rectal-swab/stool-culture targeting, followed by augmented prophylaxis when appropriate, and recommends against fluoroquinolones for prostate-biopsy prophylaxis in the EU. Fosfomycin requires local regulatory and safety review; its prostate-biopsy indication was withdrawn in Germany. These recommendations supersede treating older fluoroquinolone-duration or fosfomycin analyses as a universal regimen.[20]

The Pilatz 2020 review (59 RCTs, 14,153 participants) supported antibiotic prophylaxis and targeted over empirical regimens, but rated certainty low / very low. Increasing fluoroquinolone resistance remains a reason to use current local susceptibility data.[8][18]

The 2025 Xiao Cochrane publication is a review protocol, not a completed systematic review demonstrating efficacy or safety.[10]

Radical cystectomy — duration of prophylaxis​

Cystectomy with urinary diversion is the urologic operation most commonly associated with prolonged (>48 h) PAP in practice, driven by anxiety about urinary diversion, stents, and catheters. Contemporary evidence does not support this.

Thurnheer 2024 (JAMA Network Open, single-center RCT, 193 patients) found 24-hour PAP noninferior to an extended course (median 8 days, until catheter/stent removal). Ninety-day SSI occurred in 8.4% versus 12.2%; risk difference −3.8% (90% CI −11.1% to 3.4%), within the prespecified 10% noninferiority margin.[11]

Mohamed 2026 (systematic review and meta-analysis, 4 studies, n = 680):[12]

  • No statistically significant difference detected between short-term (≤24 h) and extended PAP on:
    • SSI: RR 0.71 (95% CI 0.43–1.17; p = 0.18)
    • Febrile UTI: RR 1.19 (95% CI 0.91–1.56; p = 0.20)
    • Length of stay: MD 0.76 days (p = 0.67)
  • Interpretation: supports short prophylaxis rather than routine continuation until device removal; nonsignificant pooled differences alone do not prove equivalence in every subgroup

Routine prophylaxis until catheter or stent removal is not supported. Treatment of a documented infection is a separate indication with its own agent and duration.[2][11]

Patient- and procedure-level risk factors for SSI​

Grabe 2012 EAU tentative classification[16] describes useful domains of urologic SSI risk:

DomainRisk factors
Patient — generalHigher ASA, advanced age, malnutrition / hypoalbuminemia, obesity, uncontrolled hyperglycemia, smoking, immune dysfunction
Patient — urologicBacteriuria, indwelling catheter, stone disease, obstruction, prior urogenital infection
Procedure-relatedSurgical-field contamination class, operative duration, tissue handling / invasiveness, length of postoperative catheterization

Seidelman 2023 JAMA SSI review[17] summarizes the cross-specialty evidence:

  • Administer within 60 minutes of incision
  • Cefazolin is the most commonly used agent; redose every 4 hours for lengthy procedures
  • A systematic review of 28 RCTs (n = 9,478) found additional postoperative doses did not reduce infection (OR 1.06; 95% CI 0.89–1.25)
  • Prolonged AP is increasingly associated with acute kidney injury and other harms
  • Stop antibiotics when the wound is closed

The Japanese 2015-edition guideline is a historical comparator; its allowance for up to two days in bowel surgery should not be used to extend a contemporary single-dose/24-hour pathway.[19]

Administration and safety​

Use the adult table above with the local protocol. Start most agents within 60 minutes before incision; allow up to 120 minutes for vancomycin or fluoroquinolone administration. Vancomycin infusion duration depends on dose and infusion-rate limits. Redose short-half-life agents for long cases or substantial blood loss; renal impairment may lengthen redosing intervals even when the initial prophylactic dose is unchanged.[2]

For most operations, stop prophylaxis at closure. A 24-hour cystectomy pathway has randomized support; a drain, catheter, or stent alone does not justify continuing prophylaxis. Active infection requires a separate treatment plan.[11][17][22]

Allergy history changes the choice​

The 2022 drug-allergy parameter permits cefazolin in most patients with penicillin allergy, including prior penicillin anaphylaxis, because its side chain is dissimilar. This does not establish safety after a cefazolin reaction, severe cutaneous adverse reaction (SJS/TEN, DRESS), or severe drug-related organ injury. Assess the culprit, reaction and timing; use allergy expertise for severe histories. Aztreonam shares a side chain with ceftazidime. Vancomycin infusion reactions and DRESS are different syndromes and require different management.[21]

Renal function, pregnancy and monitoring​

Avoid unnecessary nephrotoxic combinations and distinguish a prophylactic dose from a therapeutic course. Serious MRSA treatment uses AUC-guided vancomycin monitoring (target AUC/MIC 400–600, assuming MIC 1 mg/L); an old trough-only target of 15–20 mg/L is not a prophylaxis protocol. Pregnancy requires agent- and gestation-specific selection with obstetric input.[23]

MRSA prevention​

Follow institutional screening/decolonization policy for selected procedures involving prosthetic material. A common carrier regimen uses intranasal mupirocin plus chlorhexidine body cleansing; the strongest evidence is from cardiac/orthopedic surgery, with extrapolation to other prosthetic procedures. Reserve perioperative vancomycin for a specific indication such as known MRSA colonization rather than automatically adding it to every clean operation.[22]

Evidence interpretation​

Guidelines contain recommendations of differing certainty; their publication does not make every statement “Level 1.” PUMP and national device cohorts are observational. NORAPP and the cystectomy-duration trial are randomized studies with defined populations and noninferiority margins. The Xiao Cochrane protocol has no completed pooled outcome to apply. Use these distinctions when adapting a local pathway.

See Also​

References​

1. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351–356. doi:10.1097/JU.0000000000000509

2. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283. doi:10.2146/ajhp120568

3. Zeng S, Zhang Z, Bai Y, Sun Y, Xu C. Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy. Cochrane Database Syst Rev. 2019;2:CD012305. doi:10.1002/14651858.CD012305.pub2

4. Barham DW, Pyrgidis N, Gross MS, et al. AUA-recommended antibiotic prophylaxis for primary penile implantation results in a higher, not lower, risk for postoperative infection: a multicenter analysis. J Urol. 2023;209(2):399–409. doi:10.1097/JU.0000000000003071

5. Abou Chawareb E, Hammad MAM, Azad B, et al. Perioperative antimicrobial strategies in inflatable penile prosthesis surgery. J Urol. 2025;214(6):642–653. doi:10.1097/JU.0000000000004716

6. Dropkin BM, Chisholm LP, Dallmer JD, Johnsen NV, Milam DF, Kaufman MR. Penile prosthesis insertion in the era of antibiotic stewardship — are postoperative antibiotics necessary? J Urol. 2020;203(3):611–614. doi:10.1097/JU.0000000000000578

7. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

8. Pilatz A, Dimitropoulos K, Veeratterapillay R, et al. Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol. 2020;204(2):224–230. doi:10.1097/JU.0000000000000814

9. Jacewicz M, Günzel K, Rud E, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2022;22(10):1465–1471. doi:10.1016/S1473-3099(22)00373-5

10. Xiao YT, Yang Y, Wu X, et al. Antibiotic prophylaxis for transperineal prostate biopsy (protocol). Cochrane Database Syst Rev. 2025;10:CD015990. doi:10.1002/14651858.CD015990

11. Thurnheer MC, Schürmann A, Huber M, et al. Perioperative antibiotic prophylaxis duration in patients undergoing cystectomy with urinary diversion: a randomized clinical trial. JAMA Netw Open. 2024;7(10):e2439382. doi:10.1001/jamanetworkopen.2024.39382

12. Mohamed T, Bani Irshid BA, Elhashamy H, et al. Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis. Langenbecks Arch Surg. 2026. doi:10.1007/s00423-025-03943-x

13. Brant A, Lewicki P, Punjani N, et al. Trends in antimicrobial prophylaxis for inflatable penile prosthesis surgery from a large national cohort. Urology. 2023;172:131–137. doi:10.1016/j.urology.2022.11.010

14. Sun HH, Callegari M, Zhou E, et al. Trends over 20 years of antimicrobial prophylaxis for artificial urinary sphincter surgery. Neurourol Urodyn. 2023;42(6):1421–1430. doi:10.1002/nau.25206

15. Kutchukian S, Gondran-Tellier B, Dinh A, et al. Asymptomatic bacteriuria and urological surgery: risk factor or not? Results from the national and multicenter TOCUS database. J Urol. 2024;212(3):461–469. doi:10.1097/JU.0000000000004047

16. Grabe M, Botto H, Cek M, et al. Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures. World J Urol. 2012;30(1):39–50. doi:10.1007/s00345-011-0722-z

17. Seidelman JL, Mantyh CR, Anderson DJ. Surgical site infection prevention: a review. JAMA. 2023;329(3):244–252. doi:10.1001/jama.2022.24075

18. Marino Sabo E, Stern JJ. Approach to antimicrobial prophylaxis for urology procedures in the era of increasing fluoroquinolone resistance. Ann Pharmacother. 2014;48(3):380–386. doi:10.1177/1060028013517661

19. Yamamoto S, Shigemura K, Kiyota H, et al. Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition. Int J Urol. 2016;23(10):814–824. doi:10.1111/iju.13161

20. European Association of Urology. EAU Guidelines on Urological Infections. 2026. Periprocedural prophylaxis and prostate biopsy recommendations. Full guideline.

21. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150:1333–1393. doi:10.1016/j.jaci.2022.08.028.

22. Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44:695–720. doi:10.1017/ice.2023.67.

23. ASHP/IDSA/PIDS/SIDP. Therapeutic monitoring of vancomycin for serious MRSA infections: revised consensus guideline. 2020. Guideline.